EMA Authorised: Adtralza (tralokinumab) — LEO Pharma A/S

View source ↗

Summary

The EMA authorised Adtralza (tralokinumab) by LEO Pharma A/S for atopic dermatitis in the European Union. Decision date: 26 March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Adtralza (tralokinumab)

Snippet

Status: Authorised. Therapeutic area: Dermatitis, Atopic. MAH: LEO Pharma A/S. Decision date: 26/03/2026